BRAF and melanoma: To investigate the relationship between blood bilirubin-related markers and clinical outcome of patients with BRAF mutant melanoma, we first conducted a clinically retrospective analysis of 28 patients with advanced malignant melanoma who were diagnosed with BRAF V600 mutation and were treated with vemurafenib alone in the Affiliated Tumor Hospital of Sun Yat-sen University.